Hormone therapy for prostate cancer may increase risk of depression

Hormone therapy for prostate cancer may increase risk of depression

Brigham and Women’s Hospital, 04/14/2016

A new study led by researchers at Brigham and Women’s Hospital (BWH) has found a significant association between depression and patients being treated for localized prostate cancer (PCa) by androgen deprivation therapy (ADT). The findings were published online in the Journal of Clinical Oncology on April 11, 2016. “We know that patients on hormone therapy often experience decreased sexual function, weight gain and have less energy – many factors that could lead to depression. After taking a deeper look, we discovered a significant association between men being treated with ADT for PCa and depression,” says senior author Paul Nguyen, MD. “This is a completely under–recognized phenomenon. Around 50,000 men are treated with this therapy each year. It’s important not only for patients to know the potential side effects of the drugs they’re taking, but also for the physicians to be aware of this risk in order to recognize signs of depression in these patients and refer them for appropriate care,” says Nguyen, who is also the director of Prostate Brachytherapy at BWH. “Patients and physicians must weigh the risks and benefits of ADT, and this additional risk of depression may make some men even more hesitant to use this treatment, especially in clinical scenarios where the benefits are less clear, such as for intermediate–risk disease.” Researchers reviewed data from the SEER Medicare–linked database from 1992 to 2006 of 78,552 men over the age of 65 with stage I to III PCa. When compared to patients who did not receive the therapy, researchers found that the patients who received ADT had higher incidences of depression and inpatient and outpatient psychiatric treatment. Adjusted analyses demonstrated that patients who received ADT had a 23 percent increased risk of depression, a 29 percent increased risk of inpatient psychiatric treatment, and a non–significant 7 percent increased risk of outpatient psychiatric treatment when compared with patients not being treated with ADT. The risk of depression increased with the duration of ADT, from 12 percent with less than six months to 26 percent from 7 to 11 months of treatment, to 37 percent with patients being treated for 12 months or longer. A similar duration effect was seen for inpatient and outpatient psychiatric treatment.

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on April 19, 2017, in Uncategorized. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: